KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Amortization - Intangibles: 2016-2025

Historic Amortization - Intangibles for Sarepta Therapeutics (SRPT) over the last 8 years, with Jun 2025 value amounting to $601,000.

  • Sarepta Therapeutics' Amortization - Intangibles changed negligibly% to $601,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $2.4 million, marking a year-over-year increase of 0.04%. This contributed to the annual value of $2.4 million for FY2024, which is 54.27% up from last year.
  • Sarepta Therapeutics' Amortization - Intangibles amounted to $601,000 in Q2 2025, which was down 0.00% from $601,000 recorded in Q4 2024.
  • Sarepta Therapeutics' 5-year Amortization - Intangibles high stood at $763,000 for Q4 2023, and its period low was $170,000 during Q1 2021.
  • Moreover, its 3-year median value for Amortization - Intangibles was $601,000 (2025), whereas its average is $507,222.
  • Its Amortization - Intangibles has fluctuated over the past 5 years, first surged by 326.26% in 2023, then decreased by 21.23% in 2024.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Amortization - Intangibles stood at $179,000 in 2021, then remained steady at $179,000 in 2022, then skyrocketed by 326.26% to $763,000 in 2023, then dropped by 21.23% to $601,000 in 2024, then remained steady at $601,000 in 2025.
  • Its Amortization - Intangibles stands at $601,000 for Q2 2025, versus $601,000 for Q4 2024 and $602,000 for Q3 2024.